Ascendis Pharma A/S (ASND)
253.38
+1.43
(+0.57%)
USD |
NASDAQ |
Aug 25, 16:00
253.38
0.00 (0.00%)
After-Hours: 18:23
Ascendis Pharma Price to Book Value : 10.13 for Aug. 25, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 10.07 |
| August 21, 2026 | 10.13 |
| August 20, 2026 | 10.19 |
| August 19, 2026 | 10.38 |
| August 18, 2026 | 9.951 |
| August 17, 2026 | 9.893 |
| August 14, 2026 | 9.937 |
| August 13, 2026 | 9.846 |
| August 12, 2026 | 10.22 |
| August 11, 2026 | 10.18 |
| August 10, 2026 | 10.22 |
| August 07, 2026 | 10.21 |
| August 06, 2026 | 9.991 |
| August 05, 2026 | 9.765 |
| August 04, 2026 | 9.781 |
| August 03, 2026 | 9.735 |
| July 31, 2026 | 9.753 |
| July 30, 2026 | 10.04 |
| July 29, 2026 | 10.08 |
| July 28, 2026 | 10.17 |
| July 27, 2026 | 10.13 |
| July 24, 2026 | 10.15 |
| July 23, 2026 | 10.10 |
| July 22, 2026 | 10.07 |
| July 21, 2026 | 10.20 |
| Date | Value |
|---|---|
| July 20, 2026 | 10.07 |
| July 17, 2026 | 10.44 |
| July 16, 2026 | 10.39 |
| July 15, 2026 | 10.74 |
| July 14, 2026 | 10.62 |
| July 13, 2026 | 10.61 |
| July 10, 2026 | 10.81 |
| July 09, 2026 | 11.01 |
| July 08, 2026 | 11.08 |
| July 07, 2026 | 10.68 |
| July 06, 2026 | 10.71 |
| July 02, 2026 | 10.98 |
| July 01, 2026 | 10.71 |
| June 30, 2026 | 10.67 |
| June 29, 2026 | 29.13 |
| June 26, 2026 | 28.81 |
| June 25, 2026 | 28.90 |
| June 24, 2026 | 26.29 |
| June 23, 2026 | 26.36 |
| June 22, 2026 | 25.19 |
| June 18, 2026 | 25.50 |
| June 17, 2026 | 25.54 |
| June 16, 2026 | 25.54 |
| June 15, 2026 | 24.67 |
| June 12, 2026 | 24.09 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Evaxion AS | 2.966 |
| Genmab A/S | 3.443 |
| Zealand Pharma A/S | 1.223 |
| Cellectis SA | 8.386 |
| BioMarin Pharmaceutical, Inc. | 2.024 |
Price to Book Value Related Metrics
| PE Ratio | 19.31 |
| PS Ratio | 13.23 |
| Price to Free Cash Flow | 41.54 |
| Price | 253.38 |
| Earnings Yield | 5.18% |
| Market Cap | 16.64B |
| Operating PE Ratio | 128.24 |
| Normalized PE Ratio | 19.31 |